A high-beta “Win-in-MRD” challenger betting that 1‑PPM ultra-sensitive liquid biopsy plus new Medicare coverage can turn exploding test volume into a clinical revenue inflection—and a higher diagnostics multiple.
Overview
Personalis (PSNL) is a precision oncology company providing advanced genomic sequencing and analytics to support cancer management across the patient journey, spanning both biopharma research services and clinical diagnostics. Its central strategy—“Win-in-MRD”—focuses on commercializing NeXT Personal, a tumor-informed liquid biopsy assay designed for ultra-sensitive minimal residual disease detection using whole-genome sequencing. By tracking up to ~1,800 patient-specific variants and leveraging proprietary noise suppression (NeXT SENSE), the platform targets ~1 part-per-million sensitivity and very high specificity, aiming to detect recurrence earlier than imaging and improve intervention timing. Strategically, Personalis is pivoting away from lower-margin, legacy enterprise sequencing revenue toward higher-value, reimbursable clinical diagnostics. In 2025, revenue fell to $69.6M due to planned legacy wind-down, but clinical test volume surged nearly 400% to 16,233 tests—evidence of strong demand. With pivotal Medicare coverage wins in breast and lung (late 2025/early 2026) and a strong cash position (~$240M), the company is positioned for a potential revenue inflection as previously unreimbursed volumes convert into paid clinical revenue.